Charles M. Baum, MD, PhD
Dr. Baum was appointed President and Chief Executive Officer and Board Member of Mirati Therapeutics in November 2012. Since then, he has been responsible for moving the company to the United States, listing the company on NASDAQ and establishing its headquarters in San Diego, California. In addition, he has built a world class precision oncology leadership team and transformed Mirati into an company focused on the innovative, targeted development of Mirati's receptor tyrosine kinase and histone deacetylase inhibitors in various cancers. Prior to joining Mirati he was Senior Vice President for Biotherapeutic Clinical Research within Pfizer's Worldwide Research & Development division. Dr. Baum was at Pfizer from 2003 until joining Mirati in 2012, serving in roles of increasing responsibility including as Vice President and Head of Oncology Development and as Chief Medical Officer for Pfizer's Biotherapeutics and Bioinnovation Center. He was responsible for the development of the oncology portfolio, including Axitinib (Inlyta®), Crizotinib (Xalkori®) and the approval of sunitinib (Sutent®) for the treatment of gastrointestinal stromal tumor (GIST) and renal cell carcinoma. Prior to joining Pfizer, Dr. Baum was responsible for the Phase I-IV development of several oncology compounds at Schering-Plough, including temozolomide (Temodar®) which was approved for the treatment of patients with advanced brain tumors. His career has included academic and hospital positions at Stanford and Emory universities, as well as positions of increasing responsibility within the pharmaceutical industry (Systemix, Searle, Schering-Plough and Pfizer). Dr. Baum currently serves on the board of directors of Array BioPharma. Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine in St. Louis, Missouri and completed his post-graduate training at Stanford University, California. Dr. Baum has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts, and holds a number of patents and patent applications.
Dr. Bruce L.A. Carter
Dr. Carter joined Mirati’s Board of Directors in September of 2016. He currently serves on the board of directors of Xencor, Inc. and Enanta Pharmaceuticals, both publicly-held biopharmaceutical companies, as well as Dr. Reddy’s Laboratories, a publicly-held pharmaceutical company based in India. Dr. Carter served as executive chairman of the board at Immune Design Corp. from 2009 to 2011, later serving as chairman of the board until 2012 and as a member of the board until 2015. Prior to joining Immune Design, Dr. Carter was the chief executive officer at ZymoGenetics, Inc., one of several managerial roles since joining in 1986 as vice president of research and development. In 1988 Novo Nordisk A/S acquired ZymoGenetics and, in 1994, Dr. Carter was appointed corporate executive vice president and chief scientific officer for Novo Nordisk. In 2000, Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk. As CEO, he was instrumental in transforming ZymoGenetics from the research arm of a European biopharmaceutical company to a company that developed and commercialized Recothrom®. Dr. Carter also held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin from 1975 to 1982. He received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London. Dr. Carter also serves as chairman of the board at the TB Alliance.
Henry J. Fuchs, MD
Henry J. Fuchs, MD is currently Executive Vice President and Chief Medical Officer of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and is a seasoned biotech drug development executive. From 2005 to 2008, Dr. Fuchs was Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals (NASDAQ: ONXX), overseeing expanded development of the kinase inhibitor Nexavar® and other key development programs. From 1996 to 2005, Dr. Fuchs served in multiple roles of increasing responsibility at Ardea Biosciences (NASDAQ: RDEA), first as Vice President, Clinical Affairs, then as President and Chief Operating Officer, and finally as Chief Executive Officer. From 1987 to 1996, Dr. Fuchs held various positions at Genentech where, among other responsibilities, he led the clinical program that resulted in the approval of Pulmozyme®. Dr. Fuchs was also responsible for the Phase III development program that led to the approval of Herceptin® to treat metastatic breast cancer. Dr. Fuchs received an M.D. degree from George Washington University and a B.A. degree in biochemical sciences from Harvard University.
Mr. Grey currently serves as Chief Executive Officer and Chairman of Reneo Pharamceuticals. He recently served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., a privately-held biotechnology company before it was acquired by Shire. He is also serving as a Venture Partner with Pappas Ventures, a life sciences venture capital firm, since January 2010. Between January and September 2009, he served as President and Chief Executive Officer of Auspex Pharmaceuticals, Inc., a private biotechnology company. From January 2005 until its acquisition in August 2008, Mr. Grey was President and Chief Executive Officer of SGX Pharmaceuticals, Inc., a public biotechnology company, where he previously served as President from June 2003 to January 2005 and as Chief Business Officer from April 2001 until June 2003. Prior to joining SGX Pharmaceuticals, Inc., Mr. Grey acted as President, Chief Executive Officer and Board member of Trega Biosciences, Inc., a biotechnology company. From November 1994 to August 1998, Mr. Grey was the President of BioChem Therapeutic, Inc., the pharmaceutical operating division of BioChem Pharma, Inc. During 1994, Mr. Grey served as President and Chief Operating Officer for Ansan, Inc., a pharmaceutical company. From 1974 to 1993, he served in various roles with Glaxo, Inc. and Glaxo Holdings, plc, culminating in the position of Vice President, Corporate Development. Mr. Grey is currently a director of Horizon Pharma, Inc., a public pharmaceutical company, and Selventa, Inc., a healthcare company. Mr. Grey previously served on the board of directors of two public companies during the past five years: IDM Pharma, Inc. (from 1999 to 2009) and Achillion Pharmaceuticals, Inc. (from 2001 to 2010). He received a B.Sc. in chemistry from the University of Nottingham, United Kingdom.
Mr. Johnson has served as a director of Mirati since September 2013 and serves on the boards of directors for several life science companies. He is currently a director for Heron Therapeutics Inc. (NASDAQ: HRTX), Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), and La Jolla Pharmaceutical Company (NASDAQ: LJPC). Mr. Johnson also served as a past director of Ardea Biosciences Inc. (NASDAQ: RDEA) from 2008 until its sale to AstraZeneca PLC in 2012. In addition to his board service, Mr. Johnson has served as an advisor to Daisas Medical, LLC since 2012. From 2011 to 2012 he was Chief Financial Officer of PURE Bioscience Inc., and from 2010 to 2011 he was Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009, and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. He held several positions, including Chief Financial Officer and Senior Vice President of Operations, at MitoKor Inc. from 1994 to 2004. Prior to 1994, Mr. Johnson held senior financial positions with several early-stage technology companies, and also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received his B.B.A. in accounting from the University of Michigan-Dearborn.
Rodney Lappe, PhD
Dr. Lappe brings 29 years of drug discovery experience in the pharmaceutical and biotech industries to Mirati Therapeutics. Before joining Tavistock Life Sciences in early 2012, he was Group Sr. Vice President, Pfizer Worldwide Research and Development and Chief Scientific Officer for CovX in San Diego, California. Dr. Lappe was responsible for the advancement of three novel protein bio-conjugates through his work at CovX that are now in clinical testing as well as two additional clinical candidates in late stage preclinical development. Dr. Lappe was also responsible for the continued growth and productivity of Pfizer's four internal Biotech Units, Rinat, the Center for Integrated Biology and Biotherapeutics and the Oligonucleotide Technology Unit. He served as Co-lead of the integration of Wyeth R&D after the acquisition by Pfizer in 2009. Prior to joining CovX, Dr. Lappe served as Vice President for cardiovascular and metabolic diseases at Pharmacia where he contributed to the registration of Inspra®, a novel aldosterone receptor antagonist. Prior to joining Pharmacia, he held positions of increasing responsibility with Wyeth, Rorer Central Research, CIBA Geigy and Searle Pharmaceuticals. Dr. Lappe received his PhD in Pharmacology from Indiana University and his BA from Blackburn College.
William R. Ringo
Mr. Ringo has over 40 years of experience in the pharmaceutical and biotechnology sectors. Currently, he serves as a senior advisor with investment bank Barclays Capital and also serves as a strategic advisor with Sofinnova Ventures. Previously, Mr. Ringo was senior vice president of strategy and business development for Pfizer before his retirement in 2010. He spent nearly 30 years with Eli Lilly and Company, serving in numerous executive roles, including product group president for oncology and critical care, president of internal medicine products, president of the infectious disease business unit and vice president of sales and marketing for U.S. pharmaceuticals. He has also served as president and CEO of Abgenix, an oncology-focused antibody company that was purchased by Amgen. He currently serves on the board of directors of Sangamo BioSciences, Ascendis Pharma and BioCrossroads, an Indiana initiative and public-private collaboration focused on growing, advancing and investing in life sciences. He also recently served on the board of directors for Onyx Pharmaceuticals until its acquisition by Amgen in 2013. Mr. Ringo earned a B.S. in business administration and an M.B.A. from the University of Dayton.
Inspra®, Xalkori ®, Inlyta®, and Sutent ® are registered trademarks of Pfizer, Inc.
Temodar® is a registered trademark of Merck & Co., Inc.
Nexavar®, Pulmozyme®, and Herceptin® are registered trademarks of Genentech, Inc.